

Sergi Mas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8777830/publications.pdf>

Version: 2024-02-01

98
papers

1,750
citations

218662

26
h-index

377849

34
g-index

110
all docs

110
docs citations

110
times ranked

2609
citing authors

#	ARTICLE	IF	CITATIONS
1	Link between cognitive polygenic risk scores and clinical progression after a first-psychotic episode. <i>Psychological Medicine</i> , 2023, 53, 4634-4647.	4.5	3
2	Gene expression study in monocytes: evidence of inflammatory dysregulation in early-onset obsessive-compulsive disorder. <i>Translational Psychiatry</i> , 2022, 12, 134.	4.8	1
3	The role of BDNF and NGF plasma levels in first-episode schizophrenia: A longitudinal study. <i>European Neuropsychopharmacology</i> , 2022, 57, 105-117.	0.7	4
4	Clinical and treatment predictors of relapse during a three-year follow-up of a cohort of first episodes of schizophrenia. <i>Schizophrenia Research</i> , 2022, 243, 32-42.	2.0	15
5	Gene co-expression architecture in peripheral blood in a cohort of remitted first-episode schizophrenia patients. <i>NPJ Schizophrenia</i> , 2022, 8, .	3.6	2
6	Metabolic polygenic risk scores effect on antipsychotic-induced metabolic dysregulation: A longitudinal study in a first episode psychosis cohort. <i>Schizophrenia Research</i> , 2022, 244, 101-110.	2.0	8
7	The usefulness of Olanzapine plasma concentrations in monitoring treatment efficacy and metabolic disturbances in first-episode psychosis. <i>Psychopharmacology</i> , 2021, 238, 665-676.	3.1	8
8	DNA Methylation of Fluoxetine Response in Child and Adolescence: Preliminary Results. <i>Pharmacogenomics and Personalized Medicine</i> , 2021, Volume 14, 459-467.	0.7	3
9	Integrative DNA Methylation and Gene Expression Analysis of Cognitive Behavioral Therapy Response in Children and Adolescents with Obsessive-Compulsive Disorder; a Pilot Study. <i>Pharmacogenomics and Personalized Medicine</i> , 2021, Volume 14, 757-766.	0.7	3
10	Identification of EP300 as a Key Gene Involved in Antipsychotic-Induced Metabolic Dysregulation Based on Integrative Bioinformatics Analysis of Multi-Tissue Gene Expression Data. <i>Frontiers in Pharmacology</i> , 2021, 12, 729474.	3.5	3
11	A longitudinal study of gene expression in first-episode schizophrenia; exploring relapse mechanisms by co-expression analysis in peripheral blood. <i>Translational Psychiatry</i> , 2021, 11, 539.	4.8	5
12	P.0606 Identification of key genes involved in antipsychotic-induced metabolic dysregulation based on integrative bioinformatics analysis of multi-tissue gene expression data. <i>European Neuropsychopharmacology</i> , 2021, 53, S445.	0.7	0
13	Personalized medicine begins with the phenotype: identifying antipsychotic response phenotypes in a first-episode psychosis cohort. <i>Acta Psychiatrica Scandinavica</i> , 2020, 141, 541-552.	4.5	6
14	Identifying key transcription factors for pharmacogenetic studies of antipsychotics induced extrapyramidal symptoms. <i>Psychopharmacology</i> , 2020, 237, 2151-2159.	3.1	4
15	The positive allosteric modulator of the mGlu2 receptor JNJ-46356479 partially improves neuropathological deficits and schizophrenia-like behaviors in a postnatal ketamine mice model. <i>Journal of Psychiatric Research</i> , 2020, 126, 8-18.	3.1	9
16	Examining Gene-Environment Interactions Using Aggregate Scores in a First-Episode Psychosis Cohort. <i>Schizophrenia Bulletin</i> , 2020, 46, 1019-1025.	4.3	32
17	Association study of candidate genes with obesity and metabolic traits in antipsychotic-treated patients with first-episode psychosis over a 2-year period. <i>Journal of Psychopharmacology</i> , 2020, 34, 514-523.	4.0	12
18	Birth weight and antipsychotic induced weight gain: A prenatal programming approach in the PEPs study. <i>Schizophrenia Research</i> , 2020, 218, 292-294.	2.0	6

#	ARTICLE	IF	CITATIONS
19	Response to fluoxetine in children and adolescents: a weighted gene co-expression network analysis of peripheral blood. American Journal of Translational Research (discontinued), 2020, 12, 2028-2040.	0.0	0
20	Altered frequencies of Th17 and Treg cells in children and adolescents with obsessive-compulsive disorder. Brain, Behavior, and Immunity, 2019, 81, 608-616.	4.1	20
21	Gene-environment interaction between an endocannabinoid system genetic polymorphism and cannabis use in first episode of psychosis. European Neuropsychopharmacology, 2019, 29, 786-794.	0.7	16
22	P.276 Altered frequency of T helper 17 cells and Treg cells in children and adolescents with obsessive-compulsive disorder. European Neuropsychopharmacology, 2019, 29, S205.	0.7	0
23	Genetic variability in the serotonergic system and age of onset in anorexia nervosa and obsessive-compulsive disorder. Psychiatry Research, 2019, 271, 554-558.	3.3	9
24	Genetic Associations of Serotonergic and GABAergic Genes in an Extended Collection of Early-Onset Obsessive-Compulsive Disorder Trios. Journal of Child and Adolescent Psychopharmacology, 2019, 29, 152-157.	1.3	5
25	Human-leukocyte antigen class II genes in early-onset obsessive-compulsive disorder. World Journal of Biological Psychiatry, 2019, 20, 352-358.	2.6	16
26	SiNoPsis: Single Nucleotide Polymorphisms selection and promoter profiling. Bioinformatics, 2018, 34, 303-305.	4.1	2
27	Improving pharmacogenetic prediction of extrapyramidal symptoms induced by antipsychotics. Translational Psychiatry, 2018, 8, 276.	4.8	12
28	Impact of <i>NTRK2</i>, <i>DRD2</i> and <i>ACE</i> polymorphisms on prolactin levels in antipsychotic-treated patients with first-episode psychosis. Journal of Psychopharmacology, 2018, 32, 702-710.	4.0	8
29	Further Support for the Involvement of Genetic Variants Related to the Serotonergic Pathway in the Antidepressant Response in Children and Adolescents After a 12-Month Follow-Up: Impact of the HTR2A rs7997012 Polymorphism. Journal of Child and Adolescent Psychopharmacology, 2018, 28, 711-718.	1.3	11
30	Different Modulation of Rps6 Phosphorylation by Risperidone in Striatal Cells Sub Populations: Involvement of the mTOR Pathway in Antipsychotic-Induced Extrapyramidal Symptoms in Mice. Neuropsychiatry, 2018, 08, .	0.4	1
31	Modelling gene-environment interaction in first episodes of psychosis. Schizophrenia Research, 2017, 189, 181-189.	2.0	43
32	Intuitive pharmacogenetic dosing of risperidone according to CYP2D6 phenotype extrapolated from genotype in a cohort of first episode psychosis patients. European Neuropsychopharmacology, 2017, 27, 647-656.	0.7	13
33	Association of regulatory TPH2 polymorphisms with higher reduction in depressive symptoms in children and adolescents treated with fluoxetine. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 77, 236-240.	4.8	16
34	Epigenetic and genetic variants in the HTR1B gene and clinical improvement in children and adolescents treated with fluoxetine. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 75, 28-34.	4.8	28
35	Microarray gene-expression study in fibroblast and lymphoblastoid cell lines from antipsychotic-naïve first-episode schizophrenia patients. Journal of Psychiatric Research, 2017, 95, 91-101.	3.1	12
36	Inflammatory dysregulation of monocytes in pediatric patients with obsessive-compulsive disorder. Journal of Neuroinflammation, 2017, 14, 261.	7.2	42

#	ARTICLE	IF	CITATIONS
37	4.15 EPIGENETIC AND GENETIC VARIANTS IN THE HTR1B GENE AND CLINICAL IMPROVEMENT IN CHILDREN AND ADOLESCENTS TREATED WITH FLUOXETINE. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2016, 55, S167.	0.5	0
38	6.116 MONOCYTE ACTIVATION MARKERS IN OBSESSIVE-COMPULSIVE DISORDER. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2016, 55, S241.	0.5	1
39	Exon-focused genome-wide association study of obsessive-compulsive disorder and shared polygenic risk with schizophrenia. <i>Translational Psychiatry</i> , 2016, 6, e768-e768.	4.8	41
40	Association of CACNA1C and SYNE1 in offspring of patients with psychiatric disorders. <i>Psychiatry Research</i> , 2016, 245, 427-435.	3.3	9
41	Pharmacogenetic study focused on fluoxetine pharmacodynamics in children and adolescent patients. <i>Pharmacogenetics and Genomics</i> , 2016, 26, 487-496.	1.5	10
42	Pharmacogenetic study of antipsychotic induced acute extrapyramidal symptoms in a first episode psychosis cohort: role of dopamine, serotonin and glutamate candidate genes. <i>Pharmacogenomics Journal</i> , 2016, 16, 439-445.	2.0	30
43	One-Year Follow-up of Children and Adolescents with Major Depressive Disorder: Relationship between Clinical Variables and Abcb1 Gene Polymorphisms. <i>Pharmacopsychiatry</i> , 2016, 49, 248-253.	3.3	9
44	Association between genetic variants of serotonergic and glutamatergic pathways and the concentration of neurometabolites of the anterior cingulate cortex in paediatric patients with obsessive-compulsive disorder. <i>World Journal of Biological Psychiatry</i> , 2016, 17, 394-404.	2.6	10
45	A Pharmacovigilance Study in First Episode of Psychosis: Psychopharmacological Interventions and Safety Profiles in the PEPs Project. <i>International Journal of Neuropsychopharmacology</i> , 2016, 19, pyv121.	2.1	29
46	Network analysis of gene expression in mice provides new evidence of involvement of the mTOR pathway in antipsychotic-induced extrapyramidal symptoms. <i>Pharmacogenomics Journal</i> , 2016, 16, 293-300.	2.0	13
47	Integrating Genetic, Neuropsychological and Neuroimaging Data to Model Early-Onset Obsessive Compulsive Disorder Severity. <i>PLoS ONE</i> , 2016, 11, e0153846.	2.5	21
48	Evidence of activation of the Toll-like receptor-4 proinflammatory pathway in patients with schizophrenia. <i>Journal of Psychiatry and Neuroscience</i> , 2016, 41, E46-E55.	2.4	65
49	Pharmacogenetic predictor of extrapyramidal symptoms induced by antipsychotics: Multilocus interaction in the mTOR pathway. <i>European Neuropsychopharmacology</i> , 2015, 25, 51-59.	0.7	30
50	Network analysis of gene expression in peripheral blood identifies mTOR and NF- κ B pathways involved in antipsychotic-induced extrapyramidal symptoms. <i>Pharmacogenomics Journal</i> , 2015, 15, 452-460.	2.0	18
51	Apoptotic markers in cultured fibroblasts correlate with brain metabolites and regional brain volume in antipsychotic-naïve first-episode schizophrenia and healthy controls. <i>Translational Psychiatry</i> , 2015, 5, e626-e626.	4.8	30
52	Association between genetic variants related to glutamatergic, dopaminergic and neurodevelopment pathways and white matter microstructure in child and adolescent patients with obsessive-compulsive disorder. <i>Journal of Affective Disorders</i> , 2015, 186, 284-292.	4.1	38
53	Applicability of gene expression and systems biology to develop pharmacogenetic predictors; antipsychotic-induced extrapyramidal symptoms as an example. <i>Pharmacogenomics</i> , 2015, 16, 1975-1988.	1.3	11
54	Effect of CYP2D6 on risperidone pharmacokinetics and extrapyramidal symptoms in healthy volunteers: results from a pharmacogenetic clinical trial. <i>Pharmacogenomics</i> , 2014, 15, 17-28.	1.3	14

#	ARTICLE	IF	CITATIONS
55	Effect of CYP2D6, CYP2C9 and ABCB1 genotypes on fluoxetine plasma concentrations and clinical improvement in children and adolescent patients. <i>Pharmacogenomics Journal</i> , 2014, 14, 457-462.	2.0	43
56	Influence of ABO genotype and phenotype on angiotensin-converting enzyme plasma activity. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2014, 15, 580-584.	1.7	18
57	The effect of age on DNA concentration from whole saliva: Implications for the standard isolation method. <i>American Journal of Human Biology</i> , 2014, 26, 859-862.	1.6	3
58	Plasma Fluoxetine Concentrations and Clinical Improvement in an Adolescent Sample Diagnosed With Major Depressive Disorder, Obsessive-Compulsive Disorder, or Generalized Anxiety Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2014, 34, 318-326.	1.4	27
59	Role of <i>GAD2</i> and <i>HTR1B</i> genes in early-onset obsessive-compulsive disorder: results from transmission disequilibrium study. <i>Genes, Brain and Behavior</i> , 2014, 13, 409-417.	2.2	19
60	Increased susceptibility to apoptosis in cultured fibroblasts from antipsychotic-naïve first-episode schizophrenia patients. <i>Journal of Psychiatric Research</i> , 2014, 48, 94-101.	3.1	45
61	Functional analysis of gene expression in risperidone treated cells provide new insights in molecular mechanism and new candidate genes for pharmacogenetic studies. <i>European Neuropsychopharmacology</i> , 2013, 23, 329-337.	0.7	17
62	Common genetic background in anorexia nervosa and obsessive compulsive disorder: Preliminary results from an association study. <i>Journal of Psychiatric Research</i> , 2013, 47, 747-754.	3.1	35
63	Secondary nonmotor negative symptoms in healthy volunteers after single doses of haloperidol and risperidone: a double-blind, crossover, placebo-controlled trial. <i>Human Psychopharmacology</i> , 2013, 28, 586-593.	1.5	19
64	Relationship between <i>CYP2D6</i> genotype and haloperidol pharmacokinetics and extrapyramidal symptoms in healthy volunteers. <i>Pharmacogenomics</i> , 2013, 14, 1551-1563.	1.3	16
65	A common variant of the ABO gene protects against hypertension in a Spanish population. <i>Hypertension Research</i> , 2012, 35, 592-596.	2.7	6
66	Clinical improvement and plasma concentration of fluoxetine in major depression disorder, obsessive compulsory disorder and generalized anxiety disorder. <i>Neuropsychiatrie De L'Enfance Et De L'Adolescence</i> , 2012, 60, S185.	0.2	0
67	Neurotoxic/neuroprotective activity of haloperidol, risperidone and paliperidone in neuroblastoma cells. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2012, 36, 71-77.	4.8	47
68	Sulforaphane protects SK-N-SH cells against antipsychotic-induced oxidative stress. <i>Fundamental and Clinical Pharmacology</i> , 2012, 26, 712-721.	1.9	20
69	Strengths and weaknesses of pharmacogenetic studies of antipsychotic drugs: the potential value of the PEPs study. <i>Pharmacogenomics</i> , 2012, 13, 1773-1782.	1.3	17
70	Fluoxetine pharmacogenetics in child and adult populations. <i>European Child and Adolescent Psychiatry</i> , 2012, 21, 599-610.	4.7	30
71	Intuitive pharmacogenetics: spontaneous risperidone dosage is related to CYP2D6, CYP3A5 and ABCB1 genotypes. <i>Pharmacogenomics Journal</i> , 2012, 12, 255-259.	2.0	35
72	Searching for functional SNPs or rare variants in exonic regions of DRD3 in risperidone-treated patients. <i>European Neuropsychopharmacology</i> , 2011, 21, 294-299.	0.7	12

#	ARTICLE	IF	CITATIONS
73	Pharmacogenetic predictors of angiotensin-converting enzyme inhibitor-induced cough. <i>Pharmacogenetics and Genomics</i> , 2011, 21, 531-538.	1.5	49
74	A functional variant provided further evidence for the association of <i>ARVCF</i> with schizophrenia. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2010, 153B, 1052-1059.	1.7	8
75	Lack of association between schizophrenia and polymorphisms in dopamine metabolism and transport genes. <i>Fundamental and Clinical Pharmacology</i> , 2010, 24, 741-747.	1.9	11
76	Xenobiotic metabolizing and transporter genes: gene-gene interactions in schizophrenia and related disorders. <i>Pharmacogenomics</i> , 2010, 11, 1725-1731.	1.3	12
77	Lack of association between antipsychotic-induced extrapyramidal symptoms and polymorphisms in dopamine metabolism and transport genes. <i>Psychiatry Research</i> , 2010, 175, 173-175.	3.3	17
78	Pharmacogenetics Strategies: From Candidate Genes to Whole-Genome Association Analysis. Exploratory or Confirmatory Studies?. <i>Current Pharmacogenomics and Personalized Medicine</i> , 2009, 7, 59-69.	0.2	6
79	A common variant in DRD3 gene is associated with risperidone-induced extrapyramidal symptoms. <i>Pharmacogenomics Journal</i> , 2009, 9, 404-410.	2.0	50
80	Insertion/deletion polymorphism of the angiotensin-converting enzyme gene is associated with schizophrenia in a Spanish population. <i>Psychiatry Research</i> , 2009, 165, 175-180.	3.3	38
81	ARVCF single marker and haplotypic association with schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2009, 33, 1064-1069.	4.8	15
82	CYP2D6*3, *4, *5 AND *6 POLYMORPHISMS AND ANTIPSYCHOTIC-INDUCED EXTRAPYRAMIDAL SIDE-EFFECTS IN PATIENTS RECEIVING ANTIPSYCHOTIC THERAPY. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2008, 35, 807-811.	1.9	36
83	Polymorphism of dopamine D2 receptor (TaqIA, TaqIB, and-141C Ins/Del) and dopamine degradation enzyme (COMT G158A, A-278G) genes and extrapyramidal symptoms in patients with schizophrenia and bipolar disorders. <i>Psychiatry Research</i> , 2008, 161, 131-141.	3.3	42
84	Association of A/G Polymorphism in Intron 13 of the Monoamine Oxidase B Gene with Schizophrenia in a Spanish Population. <i>Neuropsychobiology</i> , 2008, 58, 65-70.	1.9	21
85	-141C Ins/Del polymorphism of the dopamine D2 receptor gene is associated with schizophrenia in a Spanish population. <i>Psychiatric Genetics</i> , 2008, 18, 122-127.	1.1	25
86	Effects of milk supplementation with conjugated linoleic acid (isomers cis-9, trans-11 and trans-10,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 98, 860-7.	2.3	45
87	Induction of Apoptosis in HT-29 Cells by Extracts from Isothiocyanates-rich Varieties of<i>Brassica Oleracea</i>. <i>Nutrition and Cancer</i> , 2007, 58, 107-114.	2.0	20
88	Dopamine transporter (DAT) genotype (VNTR) and phenotype in extrapyramidal symptoms induced by antipsychotics. <i>Schizophrenia Research</i> , 2007, 90, 115-122.	2.0	45
89	SIMULTANEOUS GENOTYPING OF CYP2D6*3, *4, *5 AND *6 POLYMORPHISMS IN A SPANISH POPULATION THROUGH MULTIPLEX LONG POLYMERASE CHAIN REACTION AND MINISEQUENCING MULTIPLEX SINGLE BASE EXTENSION ANALYSIS. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2007, 34, 992-997.	1.9	23
90	DNA Cards: Determinants of DNA Yield and Quality in Collecting Genetic Samples for Pharmacogenetic Studies. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2007, 101, 132-137.	2.5	32

#	ARTICLE	IF	CITATIONS
91	Lower specific micronutrient intake in colorectal cancer patients with tumors presenting promoter hypermethylation in p16(INK4a), p4(ARF) and hMLH1. Anticancer Research, 2007, 27, 1151-6.	1.1	19
92	Simultaneous genotyping of CYP2C9*2, *3, and 5' flanking region (C-1189T) polymorphisms in a Spanish population through a new minisequencing multiplex single-base extension analysis. European Journal of Clinical Pharmacology, 2005, 61, 635-641.	1.9	15
93	Induction of NAD(P)H Quinone Oxidoreductase by Vegetables Widely Consumed in Catalonia, Spain. Nutrition and Cancer, 2005, 52, 49-58.	2.0	7
94	Concentration of hydroxyproline in blood: A biological marker in occupational exposure to asbestos and its relationship with Pi*Z and Pi*S polymorphism in the alpha-1 antitrypsin gene. American Journal of Industrial Medicine, 2004, 45, 186-193.	2.1	5
95	Decrease in specific micronutrient intake in colorectal cancer patients with tumors presenting Ki-ras mutation. Anticancer Research, 2004, 24, 2011-20.	1.1	10
96	Cancer, genes, and catechol estrogen metabolites. International Journal of Clinical Oncology, 2003, 8, 65-66.	2.2	4
97	Pi*S and Pi*Z alpha 1 antitrypsin polymorphism and the risk for asbestosis in occupational exposure to asbestos. Toxicology Letters, 2002, 136, 9-17.	0.8	11
98	Glutathione S-transferase (GSTM1 and GSTT1)-dependent risk for colorectal cancer. Anticancer Research, 2002, 22, 3399-403.	1.1	14